Free Trial

Rangebound

EQUITIES

A quiet macro backdrop made for a limited Asia-Pac session, at least within the major regional equity index space, after a solid Monday rally for global equities (surrounding the well-documented Moderna COVID vaccine trial developments), with at least some of Monday's Asia-Pac rally being attributed to expectations surrounding the vaccine trial (as we flagged at the time).

  • Rotational flows into cyclicals continue to be eyed.
  • The CSI 300 has seen some marginal underperformance, with continued focus on recent local bond defaults/liquidity stress points & the clampdown on the FinTech sector.
  • E-minis were marginally mixed, with the announcement of Tesla's inclusion in the S&P 500 providing some light outperformance for the NASDAQ 100 contract.
  • Nikkei 225 +0.2%, Hang Seng +0.1%, CSI 300 -0.3%, ASX 200 +0.1%.
  • S&P 500 futures -16, DJIA futures -96, NASDAQ 100 futures +3.
MNI London Bureau | +44 0203-865-3809 | anthony.barton@marketnews.com

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.